The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Revista da Sociedade Brasileira de Medicina Tropical

José Abraão Carneiro Neto¹  Valéria Gusmão Bittencourt¹  Cassius De Oliveira¹  Rosana Andrade¹  Edgar Marcelino De Carvalho¹ 

关键词: HTLV-1;    Overactive bladder;    Botox;   

DOI  :  10.1590/0037-8682-0029-2014

来源: SciELO

【 摘 要 】

Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License